EGF anticorps (Middle Region)
-
- Antigène Voir toutes EGF Anticorps
- EGF (Epidermal Growth Factor (EGF))
-
Épitope
- Middle Region
- Reactivité
- Humain, Souris, Rat, Porc, Chien, Lapin, Cheval
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp EGF est non-conjugé
-
Application
- Western Blotting (WB)
- Séquence
- ITIDFLTDKL YWCDAKQSVI EMANLDGSKR RRLTQNDVGH PFAVAVFEDY
- Homologie
- Dog: 86%, Horse: 93%, Human: 100%, Mouse: 79%, Pig: 93%, Rabbit: 93%, Rat: 86%
- Attributs du produit
- This is a rabbit polyclonal antibody against EGF. It was validated on Western Blot using a cell lysate as a positive control.
- Purification
- Affinity Purified
- Immunogène
- The immunogen is a synthetic peptide directed towards the middle region of human EGF
- Top Product
- Discover our top product EGF Anticorps primaire
-
-
- Indications d'application
- Optimal working dilutions should be determined experimentally by the investigator.
- Commentaires
-
Antigen size: 1207 AA
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 11, pp. 3367-71, (2008) (PubMed).
: "
-
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 11, pp. 3367-71, (2008) (PubMed).
-
- Antigène
- EGF (Epidermal Growth Factor (EGF))
- Autre désignation
- EGF (EGF Produits)
- Synonymes
- anticorps HOMG4, anticorps URG, anticorps AI790464, anticorps CEGF, anticorps epidermal growth factor, anticorps pro-epidermal growth factor, anticorps EGF, anticorps egf, anticorps CpipJ_CPIJ020278, anticorps Egf
- Sujet
-
Epidermal growth factor has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells of both ectodermal and mesodermal origin. The EGF precursor is believed to exist as a membrane-
Alias Symbols: URG, HOMG4
Protein Interaction Partner: EGFR, PCGF2, UBE2I, SREBF1, LMNB1, EMD, LMNA, ZFYVE28, PIK3R2, ADAM12, DUSP3, VTN, ERBB3, ERBB2, NRG1, EGF, CPM, ADRBK1, GRB2, MAPKAPK2, RPS6KA5, FNBP1,
Protein Size: 1207 - Poids moléculaire
- 6 kDa
- ID gène
- 1950
- NCBI Accession
- NM_001963, NP_001954
- UniProt
- P01133
- Pathways
- Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation
-